Therapeutic Research of Intramembranous Fragment Vaccines of Amyloid-Β on APP Tg Mice

ZHANG Songjiang,WU Lixiang
DOI: https://doi.org/10.13431/j.cnki.immunol.j.20110181
2011-01-01
Abstract:Immunotherapy with Aβ is expected to bring great improvement for Alzheimer's disease(AD).However,clinical trials have been suspended because of meningoencephalitics which accompanied lymphocytic infiltration.To explore effective and safe vaccines for AD,intramembranous fragments of amyloid-β(IF-Aβ) were selected as Immunogens.Administration of IF-Aβ(50 μg/mouse) to amyloid precursor protein transgenic(APP Tg) C57BL/6J mice at the age of 6 months for 2.5 months alleviated progressive cognitive impairments in the water maze test with decreased Aβ deposition in the brain regions.A histological analysis with an immunohistochemical analysis with antibodies against CD3,CD4,CD8,and CD19 suggested there was no lymphocytic infiltration in the brain of vaccinated APP Tg mice.The results suggest that immunotherapy with IF-Aβ is a safe and effective treatment for AD.
What problem does this paper attempt to address?